Oncosec's trial with Merck is a (combination therapy with Keytruda) to treat the non-responders to Keytruda monotherapy in melanoma. I would suggest you go to Oncosec.com where you can read all the full details of how the electroporation with IL-12 (Immunopulse platform) works. It is truly amazing groundbreaking science that will most likely be expanded into solid tumors. So imagine that Merck can only treat 30% of cancer patients in most cancer types with Keytruda monotherapy. If Oncosec's Immunopulse platform proves successful in priming the immune system in combination therapy with Keytruda then that would be a huge deal. Seems very likely that if the interim results out Nov. 11th are good then Merck will be open to more collaboration with Oncosec in other cancer types beside melanoma.
News 
Market Data 
Discover 
